NCCT affected by PHAII is the molecular target of thiazide diuretics (six times more sensitive to treatment with thiazides than primary HT individuals), promoting the reversibility of HT and hyperkalemia caused by GS. This evidence concerns the gene SLC12A3 and hematocrit.